Search Results

Displaying Results 1-25 of 33 "'HOTH'"

Jun 15, 2026, 08:11 ET Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets

Fellow Shareholders,The past several months have marked a transformative period for our Company. Following our transition from Hoth Therapeutics to Rocket One Inc. (Nasdaq: RKTO), we have begun executing a strategy focused on advanced computing, artificial intelligence infrastructure,

More news about: Rocket One Inc.

Jun 03, 2026, 09:00 ET vialytics Appoints Dominik Kenzler as Chief Product and Technology Officer

Expansion and Scale As part of this leadership transition, Achim Hoth will shift his focus to long-term strategy and growth."I'm incredibly proud of what we've built within the product organization," said Hoth. "Now my focus is on shaping our next phase of growth—identifying new markets

More news about: Vialytics Americas, Inc.

May 27, 2026, 08:11 ET Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications

ApplicationsHOBOKEN, N.J., May 27, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company") today announced that, following the strategic repositioning disclosed on May 19, 2026, it has completed the

Search Results

Displaying Results 1-25 of 33 "'HOTH'"

Jun 15, 2026, 08:11 ET Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets

Jun 03, 2026, 09:00 ET vialytics Appoints Dominik Kenzler as Chief Product and Technology Officer

May 27, 2026, 08:11 ET Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications

May 26, 2026, 08:18 ET Hoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology Platform

May 05, 2026, 16:17 ET Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

Apr 14, 2026, 07:00 ET Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Apr 13, 2026, 17:23 ET Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Apr 02, 2026, 16:05 ET Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Apr 01, 2026, 13:52 ET Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

Apr 01, 2026, 08:14 ET Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA ≤1 by Week Six

Mar 31, 2026, 08:07 ET Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Mar 26, 2026, 08:30 ET Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery

Mar 24, 2026, 08:13 ET Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption

Mar 10, 2026, 08:13 ET Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model

Mar 04, 2026, 08:31 ET Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

Feb 24, 2026, 16:15 ET HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES

Feb 12, 2026, 08:33 ET Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases

Feb 10, 2026, 08:30 ET Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model

Feb 05, 2026, 08:03 ET Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets

Jan 22, 2026, 08:13 ET Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients

Jan 21, 2026, 08:13 ET Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position

Jan 15, 2026, 08:17 ET Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation

Jan 02, 2026, 08:13 ET Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform

Dec 03, 2025, 14:00 ET Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program